TOMI Environmental Solutions Q2 Results: Revenue guidance reaffirmed
TOMI Environmental Solutions reaffirmed its $12 million revenue guidance for 2026, supported by a >100% increase in first-half sales compared to 2025. The company maintains a $35 million sales pipeline with $8.6 million in advanced stages and $6.2 million in booked orders. The merger with Carbonium Core remains on track for H2 2026 closure, while international expansions in Europe and defense sector approvals drive growth.

*this image is generated using AI for illustrative purposes only.
TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) reaffirmed its expectation to achieve revenue of at least $12 million in 2026, signaling confidence in its growth trajectory following a robust first half. The disinfection and decontamination solutions provider reported that sales in the first half of 2026 increased by over 100% compared to the same period in 2025, already exceeding the full-year sales figure for 2025. This performance underpins the company’s current financial outlook and validates its strategic expansion efforts across international markets and new sectors.
The company currently holds $6.2 million in booked orders and orders expected to be completed before year-end. Additionally, approximately $8.6 million of its total $35 million sales pipeline is in advanced stages. In the second quarter of 2026, all four key metrics—BIT Solution sales, mobile equipment sales, single applicator sales, and support services—demonstrated both year-over-year and sequential growth. Management attributed the increases in applicator sales and support services to initiatives implemented in late 2024 and early 2025.
Strategic Mergers and Partnerships
TOMI remains actively engaged with Carbonium Core following the signing of a definitive merger agreement, with plans to close the transaction in the second half of 2026. The merger marks a strategic pivot into the nuclear materials sector, leveraging Carbonium’s pilot study for producing nuclear-grade graphite for 4th-generation nuclear reactors, supported by the U.S. Department of Energy.
Internationally, TOMI expanded its SteraMist registrations across the European Union, securing approvals in Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Spain, Great Britain, and Northern Ireland. The company added Switzerland through an amendment and anticipates further approvals in France, Ireland, Poland, Portugal, and Romania. In Poland, a partnership with MedLine will enable marketing under the DeconLine brand pending mutual recognition. Other key partnerships include collaborations in Germany, the United Kingdom, and the Netherlands, as well as an active deployment in Israel to support Ebola containment efforts.
Sector Expansion and Regulatory Advances
The company is pursuing growth in emerging markets such as robotaxis, biosecurity, drones, and humanoid robotics. In the defense sector, TOMI received approvals from contractors in Korea and agencies in Canada, alongside ongoing engagements with U.S. government agencies including USAMRIID, NIH, and Aberdeen. A partnership with The Defense Logistics Agency (DLA) aims to streamline procurement of SteraMist iHP Technology.
Regulatory progress includes TOMI’s role in advancing Biosafety Cabinet (BSC) decontamination standards with NSF International. The industry is shifting toward performance-based criteria, favoring SteraMist iHP technology over legacy methods like paraformaldehyde. Key pipeline opportunities include a near-$1 million project for a major medical company and a Custom Engineered System valued at approximately $1 million.
What the Numbers Show
The doubling of first-half sales compared to 2025 indicates a significant acceleration in commercial adoption, likely driven by the expanded European regulatory approvals and defense sector entries. The presence of $8.6 million in advanced pipeline stages relative to the $12 million annual guidance suggests a high conversion rate is required to meet targets, highlighting the critical nature of closing current bids such as the Canadian Hybrid Systems opportunity.
| Metric | Value |
|---|---|
| 2026 Revenue Guidance | $12 million |
| Total Sales Pipeline | $35 million |
| Advanced Pipeline Stage | $8.6 million |
| Booked Orders | $6.2 million |
| H1 Sales Growth vs 2025 | >100% |
Elissa J. Shane, Chief Operating Officer, stated, "We are pleased with the continued momentum across the SteraMist iHP business... TOMI is executing well on multiple fronts." Dr. Halden Shane, Chairman and CEO, emphasized the strategic importance of the Carbonium merger, noting the accelerating demand for nuclear graphite due to global decarbonization efforts.
How might the integration of Carbonium Core's nuclear-grade graphite technology impact TOMI's valuation and capital requirements in the second half of 2026?
What are the primary risks associated with converting the remaining $26.4 million of the sales pipeline to meet the $12 million revenue guidance if the advanced $8.6 million segment faces delays?
Will the pending regulatory approvals in France, Ireland, Poland, Portugal, and Romania significantly accelerate European market share, or are there specific barriers to entry in these regions?





























